Table 3.
Treatment patterns for MBC prior to first disease progression among black and white patients
| Treatment, n (%) | Black patients | White patients |
|---|---|---|
| Trastuzumab-based first-line regimensa | (n = 102) | (n = 670) |
| With chemotherapy only | 79 (77.5) | 438 (65.4) |
| With hormonal therapy only | 5 (4.9) | 42 (6.3) |
| With chemotherapy and hormonal therapy | 12 (11.8) | 138 (20.6) |
| Trastuzumab alone | 6 (5.9) | 52 (7.8) |
| Non-trastuzumab-based first-line regimens | (n = 24) | (n = 123) |
| Chemotherapy only | 9 (37.5) | 63 (51.2) |
| Hormonal therapy only | 10 (41.7) | 44 (35.8) |
| Chemotherapy and hormonal therapy | 4 (16.7) | 6 (4.9) |
| Untreated | 1 (4.2) | 10 (8.1) |
aThose in the trastuzumab-based first-line regimens are defined as patients receiving ≥21 days of trastuzumab in first-line therapy
MBC metastatic breast cancer